CJC no DAC 2mg

CLASSIFICATION GHRH Analogue
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Beligas
WAREHOUSE International Warehouse 3
SUBSTANCE GHRH Peptide ,

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) composed of 30 amino acids. It has proven to be very effective in boosting growth hormone release and increasing IGF-1 levels, without adversely affecting the pulsatile nature of growth hormone secretion.

This peptide is frequently paired with Ipamorelin due to its greater specificity as a GHRH. While Ipamorelin also stimulates growth hormone release, it does so without the appetite stimulation and elevation in cortisol, acetylcholine, prolactin, and aldosterone that other peptides in its class may cause. It is well-tolerated and complements Ipamorelin nicely.

Pituitary

- Enhanced secretion of growth hormone and IGF-1 without raising prolactin levels - Improved body weight and length through increased protein synthesis - Enhanced muscle development - Increased bone density - Better immune function - Improved cognitive abilities and memory - Boosted collagen production - Increased fat loss - Enhanced cellular repair and regeneration

CJC-1295 also supports deep slow-wave sleep, which is essential for optimal muscle growth, memory retention, and overall rejuvenation.

GHRH is naturally produced in the hypothalamus, and its pulsatile secretion from there prompts a corresponding release of growth hormone from the pituitary gland. GHRH has a very short half-life of only a few minutes, which means it is rapidly cleared from the bloodstream, reducing its effects.

The first 29 amino acids of GHRH constitute its active part and are available as a synthetic peptide known as Sermorelin. This was modified further to extend its half-life to 30 minutes, resulting in CJC-1295. An additional modification involves the inclusion of DAC (Drug Affinity Complex), which binds to the blood protein albumin, extending its half-life to approximately 8 days, leading to the formulation known as CJC-1295 + DAC. CJC-1295 can also be prepared in a non-DAC form to mimic a more natural growth hormone surge each night.

The extended half-life due to DAC attachment means that injections are needed only once or twice a week. However, the prolonged presence in the bloodstream can lead to a continuous stimulus for growth hormone release from the pituitary through the GHRH receptor, which may not be natural. This could potentially reduce growth hormone pulse amplitude, ultimately resulting in decreased stimulation of growth hormone in tissues.

It is advised to take "hormone holidays" of three months every three to six months when using a long-acting CJC molecule to allow the pituitary gland to "recover." During these breaks, Sermorelin should be used instead of CJC-1295 + DAC.

These breaks can also help reduce the risk of developing resistance to growth hormone. Such resistance could occur if antibodies form that neutralize growth hormone or if the number of growth hormone receptors on tissues decreases (down-regulation). These concerns are theoretical, as no extensive long-term studies have been conducted to confirm them.

Possible side effects of CJC-1295 may include reactions at the injection site (such as irritation, redness, swelling, pain, or itching), headaches, diarrhea, vasodilation (flushing, warmth, brief hypotension), nausea, and abdominal discomfort.